In a regulatory filing, CytomX (CTMX) stated that the company is aware of media reports indicating a possible liquidity concern at Silicon Valley Bank (SIVB). "CytomX does not consider its exposure to any liquidity concern at SVB to be significant. The cash held at SVB in CytomX’s operating account is at or near the FDIC-insured limit of $250,000. CytomX also maintains a deposit account at SVB under a standby letter of credit issued pursuant to its office lease for approximately $917,000. Outside institutions serve as custodians for third-party investments held in CytomX’s name which we believe are not directly exposed to any consequences of a liquidity concern at SVB," the company stated.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CTMX:
- CytomX Therapeutics to Present at Upcoming March Investor Conferences
- CytomX announces milestone achievement in TCB collaboration with Astellas
- CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference